Onco Wiki / Maladie

Adénome de la pituitaire

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

IDDIS-PITUITARY-ADENOMA
TypeMaladie
Alias
Adénome de corticotropheAdénome hypophysaire associé au MEN1Adénome hypophysaire non fonctionnantPitNETTumeur neuroendocrine pituitaireProlactinomeAdénome de somatotropheАденома гіпофіза
Étatreviewed 2026-05-18 | pending_clinical_signoff
MaladiesAucune déclaration
SourcesSRC-NCCN-CNS-2025 SRC-NCCN-NET-2025

Informational support. All recommendations must be verified by a qualified oncologist. Engineering checks are not clinical validation or treatment approval.

Source YAML

icd_o_3_morphology8272/0
icd_o_3_topography["C75.1"]
icd_10D35.2
who_classificationWHO Endocrine and Neuroendocrine Tumours 5th ed (2022) + CNS 5th ed (2021): Pituitary neuroendocrine tumor (PitNET) lineage-based classification — lactotroph / somatotroph / corticotroph / thyrotroph / gonadotroph / null-cell

Capacités

Notes

Functional adenomas classified by lineage / hormone hypersecretion; treatment is endocrine-cohort-specific: prolactinoma — dopamine agonists (cabergoline > bromocriptine) first-line, surgery for resistant / intolerant; somatotroph (acromegaly) — transsphenoidal surgery first-line, somatostatin analogs (octreotide LAR, lanreotide, pasireotide LAR), GH-receptor antagonist (pegvisomant) for residual; corticotroph (Cushing disease) — surgery, pasireotide, ketoconazole / metyrapone / osilodrostat for cortisol control; nonfunctioning — surgery for mass effect / visual compromise. MEN1 carriers: cascade screening from age 5 (prolactin + IGF-1 + serum Ca + intact PTH + fasting gastrin + pituitary MRI per protocol).

Utilisé par

Algorithmes

Maladie

Médicament

Indication

Signal d’alerte

Protocole thérapeutique